Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
BIIB
$275.84
Biogen
($4.45)
(1.59%)
BIIB
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus: $4.86
Revenue: $2.82 Bil
Wednesday
Feb 3
7:30 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
What do you expect when BIIB reports earnings?
Beat
Meet
Miss
Where is BIIB's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$287.66
$285.13
$280.49
$277.96
Support
$273.31
$270.78
$266.14
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Peers
Amgen
Gilead Sciences
Neurocrine Biosciences
Seattle Genetics
Bluebird Bio
Qiagen N.V.
Sangamo Therapeutics
Repligen
BioCryst Pharmaceuticals
Novavax
Expectations
›
Biogen